|
2025 Conference Publication Complete disease clearance as a novel composite endpoint to predict long-term relapse in vedolizumab-treated patients with ulcerative colitis: A post-hoc analysis from the VIEWS randomised controlled trialPudipeddi, Aviv, Paramsothy, Sudarshan, Kariyawasam, Viraj, Paramsothy, Ramesh, Ghaly, Simon, Haifer, Craig, An, Yoon-Kyo, Begun, Jakob, Connor, Susan J., Corte, Crispin, Ward, Mark G., De Cruz, Peter, Fung, Caroline, Redmond, Diane, Chan, Webber, Mourad, Fadi, Kermeen, Melissa and Leong, Rupert W. (2025). Complete disease clearance as a novel composite endpoint to predict long-term relapse in vedolizumab-treated patients with ulcerative colitis: A post-hoc analysis from the VIEWS randomised controlled trial. HOBOKEN: WILEY. |
|
2025 Journal Article Upadacitinib induction is effective and safe in ulcerative colitis patients including those with prior exposure to tofacitinib: a multicenter real-world cohort studyGilmore, Robert, Fernandes, Richard, Hartley, Imogen, Arzivian, Arteen, Leong, Rupert, Andrew, Bridgette, Vasudevan, Abhinav, Greeve, Tessa, Moore, Gregory Thomas, Kim, Steven, Lightowler, Daniel, Singh, Abhey, Mahy, Gillian, Mithanthaya, Aditya, Venugopaul, Kannan, Han, Sangwoo, Bryant, Robert, West, Jack, Segal, Jonathan, Christensen, Britt, Corte, Crispin, Ding, Nik, An, Yoon-Kyo and Begun, Jakob (2025). Upadacitinib induction is effective and safe in ulcerative colitis patients including those with prior exposure to tofacitinib: a multicenter real-world cohort study. Intestinal Research, 23 (3), 347-357. doi: 10.5217/ir.2024.00127 |
|
2025 Journal Article Expert position statement: defining the role of intestinal ultrasound in assessing constipation and faecal loadingMathias, Ryan M., Goodsall, Thomas M., Parker, Claire E., Day, Alice S., An, Yoon K., Baraty, Brandon, Basnayake, Chamara, Begun, Jakob, Boyapati, Ray K., Burgell, Rebecca, Dolinger, Michael T., Maconi, Giovanni, Novak, Kerri L., Sagami, Shintaro, Smith, Rebecca L., Srinivasan, Ashish R., Taylor, Stuart A., Jairath, Vipul, Ma, Christopher and Bryant, Robert V. (2025). Expert position statement: defining the role of intestinal ultrasound in assessing constipation and faecal loading. Alimentary Pharmacology and Therapeutics, 62 (8), 799-808. doi: 10.1111/apt.70250 |
|
2025 Journal Article Upadacitinib and vedolizumab combination therapy for the management of refractory ulcerative colitis and Crohn’s diseaseGilmore, Robert, Murali, Amrutha, Etchegaray, Amirah, Swe, Ei, An, Yoon-Kyo and Begun, Jakob (2025). Upadacitinib and vedolizumab combination therapy for the management of refractory ulcerative colitis and Crohn’s disease. Intestinal Research, 23 (4), 475-482. doi: 10.5217/ir.2024.00174 |
|
2025 Conference Publication Correlation Of Biochemical, Endoscopic And Histologic Endpoints In Vedolizumab-treated Patients With Ulcerative Colitis: A Post-hoc Analysis From The Views Randomised Controlled TrialPudipeddi, Aviv, Paramsothy, Sudarshan, Kariyawasam, Viraj C., Paramsothy, Ramesh, Ghaly, Simon, Haifer, Craig, An, Yoon-Kyo, Begun, Jakob, Connor, Susan J., Corte, Crispin, Ward, Mark, De Cruz, Peter, Fung, Caroline L., Redmond, Diane, Chan, Pak Wo, Mourad, Fadi H., Kermeen, Melissa and Leong, Rupert (2025). Correlation Of Biochemical, Endoscopic And Histologic Endpoints In Vedolizumab-treated Patients With Ulcerative Colitis: A Post-hoc Analysis From The Views Randomised Controlled Trial. Digestive Disease Week (DDW) 2025, San Diego, CA United States, 3-6 August 2025. Philadelphia, PA United States: Elsevier. doi: 10.1016/s0016-5085(25)03004-5 |
|
2025 Conference Publication Extensive Disease Clearance As A Novel Composite Endpoint To Predict Long-term Relapse In Vedolizumab-treated Patients With Ulcerative Colitis: A Post-hoc Analysis From The Views Randomised Controlled TrialPudipeddi, Aviv, Paramsothy, Sudarshan, Kariyawasam, Viraj C., Paramsothy, Ramesh, Ghaly, Simon, Haifer, Craig, An, Yoon-Kyo, Begun, Jakob, Connor, Susan J., Corte, Crispin, Ward, Mark, De Cruz, Peter, Fung, Caroline L., Redmond, Diane, Chan, Pak Wo, Mourad, Fadi H., Kermeen, Melissa and Leong, Rupert (2025). Extensive Disease Clearance As A Novel Composite Endpoint To Predict Long-term Relapse In Vedolizumab-treated Patients With Ulcerative Colitis: A Post-hoc Analysis From The Views Randomised Controlled Trial. Digestive Disease Week (DDW) 2025, San Diego, CA United States, 3-6 August 2025. Philadelphia, PA United States: Elsevier. doi: 10.1016/s0016-5085(25)02960-9 |
|
2025 Conference Publication Comparative Accuracy And Reliability Of Handheld Versus Cart-based Ultrasound In Assessing Inflammatory Bowel Disease ActivityKhaing, Myat Myat, Fernandes, Richard G., An, Yoon-Kyo, Baraty, Brandon, Bryant, Robert V., Ghaly, Simon, Smith, Rebecca, Srinivasan, Ashish, Hay, Karen and Begun, Jakob (2025). Comparative Accuracy And Reliability Of Handheld Versus Cart-based Ultrasound In Assessing Inflammatory Bowel Disease Activity. Digestive Disease Week (DDW) 2025, San Diego, CA United States, 3-6 August 2025. Philadelphia, PA United States: Elsevier. doi: 10.1016/s0016-5085(25)03008-2 |
|
2025 Conference Publication Patterns And Predictors Of Steroid Use In People With Ibd In Routine Care Across ANZRivas, Consuelo, Su, Wai Kin, Wilson, William E., Ng, Watson, Ghaly, Simon, Walker, Gareth, Forbes, Angela J., Su, Heidi, Schultz, Michael, Lawrance, Ian C., Dutt, Shoma, Brett, Laurel, Begun, Jakob, Lynch, Kate D., Andrews, Jane M. and Connor, Susan J. (2025). Patterns And Predictors Of Steroid Use In People With Ibd In Routine Care Across ANZ. Digestive Disease Week (DDW) 2025, San Diego, CA United States, 3-6 August 2025. Philadelphia, PA United States: Elsevier. doi: 10.1016/s0016-5085(25)03886-7 |
|
2025 Journal Article Colon‐targeted complement C5a1 receptor inhibition using pH‐sensitive nanoparticles ameliorates experimental colitisCui, Cedric S., Lerskiatiphanich, Titaya, Li, Xaria X., Giri, Rabina, Liu, Ning, Kumar, Vinod, Whittaker, Andrew K., Han, Felicity Y., Clark, Richard J., Begun, Jakob, Lee, John D. and Woodruff, Trent M. (2025). Colon‐targeted complement C5a1 receptor inhibition using pH‐sensitive nanoparticles ameliorates experimental colitis. British Journal of Pharmacology, 182 (16), 3852-3869. doi: 10.1111/bph.70056 |
|
2025 Journal Article The durability of anti-TNF therapy for Crohn’s Disease is higher in anti-TNF naïve patients and increases with proactive therapeutic drug monitoringGilmore, Robert, Fernandes, Richard, Schildkraut, Tamar, Joshi, Riddhi, Lin, Lyman, Vorgin, Sara, Etchegaray, Amirah, Shanmuga Anandan, Aathavan, Tambakis, George, Loebenstein, Moshe, An, Yoon-Kyo, Begun, Jakob and Wright, Emily K (2025). The durability of anti-TNF therapy for Crohn’s Disease is higher in anti-TNF naïve patients and increases with proactive therapeutic drug monitoring. Crohn's and Colitis 360, 7 (2) otaf028, 1-9. doi: 10.1093/crocol/otaf028 |
|
2025 Journal Article SCFA biotherapy delays diabetes in humanized gnotobiotic mice by remodeling mucosal homeostasis and metabolomeTillett, Bree J., Dwiyanto, Jacky, Secombe, Kate R., George, Thomas, Zhang, Vivian, Anderson, Dovile, Duggan, Emily, Giri, Rabina, Loo, Dorothy, Stoll, Thomas, Morrison, Mark, Begun, Jakob, Hill, Michelle M., Gurzov, Esteban N., Bell, Kirstine J., Saad, Sonia, Barlow, Christopher K., Creek, Darren J., Chong, Chun Wie, Mariño, Eliana and Hamilton-Williams, Emma E. (2025). SCFA biotherapy delays diabetes in humanized gnotobiotic mice by remodeling mucosal homeostasis and metabolome. Nature Communications, 16 (1) 2893, 1-20. doi: 10.1038/s41467-025-58319-y |
|
2025 Conference Publication Uncontrolled clinical activity and anti-TNF plus thiopurine combination therapy are predictive factors of 1-year infection risk following acute severe ulcerative colitis: AOCC and ANZIBDC collaboration studyKim, S. J., Kim, D. H., Park, S. H., Kim, K. O., Jang, B., Kim, D. S., Lee, Y. J., Song, E. M., Lee, H. S., Kim, E. S., Yang, C. H., Sagami, S., Kobayashi, T., Mak, J., Liu, J., Cao, Q., Lin, C. C., Lin, W. C., Hsu, W. G., Wei, S. C., Rice, K., An, Y. K., Begun, J., Ruddick-Collins, L., Fernandes, R. G., Robert, G., Vasudevan, A., Zhang, J., Brownson, A. ... Garg, M. (2025). Uncontrolled clinical activity and anti-TNF plus thiopurine combination therapy are predictive factors of 1-year infection risk following acute severe ulcerative colitis: AOCC and ANZIBDC collaboration study. 20th Congress of ECCO, Berlin, Germany, 19-22 February 2025. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjae190.0401 |
|
2025 Conference Publication Mortality and comorbidities in people with Inflammatory Bowel Disease - Crohn's Colitis Cure data insights programAlsulaibi, O., Su, W. K., Wilson, W., Sin, L., Ng, W., Walker, G., Forbes, A., Lawrance,, Lynch, K., Begun, J., Connor, S. J. and Andrews, J. M. (2025). Mortality and comorbidities in people with Inflammatory Bowel Disease - Crohn's Colitis Cure data insights program. 20th Congress of ECCO, Berlin, Germany, 19-22 February 2025. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjae190.0742 |
|
2025 Conference Publication Variation in healthcare utilisation amongst IBD care centres in Australia and New Zealand, Crohn's Colitis Care Data Insight's ProgramSu, W. K., Wilson, W., Wark, G., Walker, G., Su, H., Forbes, A., Kim, A., Giles, E., Lawrance, I., Dutt, S., Brett, L., Begun, J., Lynch, K., Andrews, J. M. and Connor, S. J. (2025). Variation in healthcare utilisation amongst IBD care centres in Australia and New Zealand, Crohn's Colitis Care Data Insight's Program. 20th Congress of ECCO, Berlin, Germany, 19-22 February 2025. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjae190.0515 |
|
2025 Conference Publication Extensive disease clearance as a novel composite endpoint to predict long-term relapse in vedolizumab-treated patients with ulcerative colitis: a post-hoc analysis from the VIEWS randomised controlled trialPudipeddi, A., Lin, H., Paramsothy, S., Kariyawasam,, Paramsothy, R., Ghaly, S., Haifer, C., An, Y. K., Begun, J., Connor, S., Corte, C., Ward, M., De Cruz, P., Fung, C., Redmond, D., Chan, W., Mourad, F., Kermeen, M. and Leong, R. (2025). Extensive disease clearance as a novel composite endpoint to predict long-term relapse in vedolizumab-treated patients with ulcerative colitis: a post-hoc analysis from the VIEWS randomised controlled trial. 20th Congress of ECCO, Berlin, Germany, 19-22 February 2025. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjae190.0928 |
|
2025 Conference Publication Comparative accuracy and reliability of handheld versus cart-based ultrasound in assessing inflammatory bowel disease activityKhaing, M. M., Fernandes, R. G., An, Y. K., Baraty, B., Bryant, R., Ghaly, S., Smith, R. L., Srinivasan, A., Hay, K. and Begun, J. (2025). Comparative accuracy and reliability of handheld versus cart-based ultrasound in assessing inflammatory bowel disease activity. 20th Congress of ECCO, Berlin, Germany, 19-22 February 2025. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjae190.0834 |
|
2025 Conference Publication Clinical outcomes and predictive factors differ in acute severe ulcerative colitis for East Asian and Western patientsKim, E. S., Lee, H. S., Kim, D. H., Kim, H. S., Park, S. H., Kim, K. O., Jang, B., Kim, D. S., Lee, Y. J., Song, E. M., Kim, S. J., Lee, J., Yang, C. H., Sagami, S., Kobayashi, T., Mak, J., Liu, J., Cao, Q., Lin, W. C., Wei, S. C., Rice, K., An, Y. K., Begun, J., Ruddick-Collins, L., Fernandes, R. G., Gilmore, R., Vasudevan, A., Zhang, J., Brownson, A. ... Garg, M. (2025). Clinical outcomes and predictive factors differ in acute severe ulcerative colitis for East Asian and Western patients. 20th Congress of ECCO, Berlin, Germany, 19-22 February 2025. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjae190.0082 |
|
2025 Conference Publication Patterns and predictors of steroid use in people with IBD in routine care across ANZRivas, C., Su, W. K., Wilson, W., Ng, W., Ghaly, S., Walker, G., Forbes, A., Su, H., Schultz, M., Lawrance,, Dutt, S., Brett, L., Begun, J., Lynch, K., Andrews, J. M. and Connor, S. (2025). Patterns and predictors of steroid use in people with IBD in routine care across ANZ. 20th Congress of ECCO, Berlin, Germany, 19-22 February 2025. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjae190.1306 |
|
2025 Journal Article Cannabidiol targets colorectal cancer cells via cannabinoid receptor 2, independent of common mutationsMoniruzzaman, Md, Wong, Kuan Yau, Janjua, Taskeen Iqbal, Martin, Jennifer H., Begun, Jakob and Popat, Amirali (2025). Cannabidiol targets colorectal cancer cells via cannabinoid receptor 2, independent of common mutations. ACS Pharmacology and Translational Science, 8 (2), 543-556. doi: 10.1021/acsptsci.4c00644 |
|
2025 Journal Article Optimizing 5-aminosalicylate for moderate ulcerative colitis: expert recommendations from the Asia-Pacific, Middle East, and Africa Inflammatory Bowel Disease CoalitionAkyüz, Filiz, An, Yoon Kyo, Begun, Jakob, Aniwan, Satimai, Bui, Huu Hoang, Chan, Webber, Choi, Chang Hwan, Chopdat, Nazeer, Connor, Susan J, Desai, Devendra, Flanagan, Emma, Kobayashi, Taku, Lai, Allen Yu-Hung, Leong, Rupert W, Leow, Alex Hwong-Ruey, Leung, Wai Keung, Limsrivilai, Julajak, Muzellina, Virly Nanda, Peddi, Kiran, Ran, Zhihua, Wei, Shu Chen, Sollano, Jose, Teo, Michelle Mui Hian, Wu, Kaichun, Ye, Byong Duk and Ooi, Choon Jin (2025). Optimizing 5-aminosalicylate for moderate ulcerative colitis: expert recommendations from the Asia-Pacific, Middle East, and Africa Inflammatory Bowel Disease Coalition. Intestinal Research, 23 (1), 37-55. doi: 10.5217/ir.2024.00089 |
